Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + bevacizumab + FOLFOXIRI for first-line BRAF V600E MSS/pMMR metastatic colorectal cancer
ChiCTR2500111888Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab + tuvonralimab in colorectal cancer (CRC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Objective remission rate. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500111888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111888.